Clinical trial · Interventional
Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
NCT01347424CI-TRIAL-00012900unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Contrast enhancement ultrasonography（CEUS）could be used to evaluate the blood flow perfusion liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow perfusion of Secondary Malignant Neoplasm of Liver after treated with endostatin plus paclitaxel and carboplatin regimen.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastasis | Nasopharyngeal Neoplasm | PROBABILISTIC | 0.70 |
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel and Carboplatin | Drug | — | UNRESOLVED |
| Paclitaxel , carboplatin, endostatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Test group
- interventionNames
- Drug: Paclitaxel , carboplatin, endostatin
- type
- ACTIVE_COMPARATOR
- label
- control group
- interventionNames
- Drug: Paclitaxel and Carboplatin
Primary outcomes (1)
- measure
- The changes of blood flow perfusion in secondary malignant neoplasm of liver
- timeFrame
- 12months
Secondary outcomes (2)
- measure
- Comparing the difference of OS(Overall Survival) and ORR(Objective Response Rate) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the two different arms.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of nasopharyngeal carcinoma or NSCLC * With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm * Without transcatheter arterial chemoembolization (TACE) treatment * Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. * Estimated life expectancy of at least 3 months * Patient compliance and geographic proximity that allow adequate follow-up. * Adequate organ function including the following: Bone marrow: absolute neutrophil count (ANC) \>or= 1.5x10\^9/L, platelets \>or= 100x10\^9/L, hemoglobin \>or= 9g/dL. Hepatic: bilirubin \<1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) \< 2.5 x ULN (alkaline phosphatase, AST, ALT \< 5 x ULN is acceptable if liver has tumor involvement). Renal: calculated creatinine clearance \> 45 ml/min. * Men or women of at least 18 years of age. * Signed informed consent from patient. Exclusion Criteria: * Women who are pregnant or in lactation * Systemic treatment for another cancer within the year prior to study entry * Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures * Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies * Severe co-morbidity of any type that may interfere with assessment of the patient for the study
References
Publications (0)
Data not yet available
No reference posted for this study.